Optinose Announces $55 Million Registered Direct Offering
YARDLEY, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.
- The gross proceeds from the offering are expected to be approximately $55 million, before deducting estimated offering expenses.
- The registered direct offering is expected to close on or about May 10, 2024, subject to the satisfaction of customary closing conditions.
- We expect the post-offering cash and cash equivalents of approximately $100 million to fund operations and debt service obligations through 2025.
- A preliminary prospectus supplement relating to the offering was filed with the SEC on May 9, 2024 and is available on the SEC’s website at www.sec.gov.